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Abstract: The thymus is the central lymphoid structure where T-cell differentiation takes place, and a crucial organ for 
the maintenance of homeostasis in the immune system. Thymopoiesis includes intrathymic proliferation of T-cell precur-
sors, selection and output of both self-tolerant and competent effector T cells, as well as of natural regulatory T cells 
(nTreg). In the crosstalk between the neuroendocrine and immune systems, peptide hormones have been more and more 
implicated in immunomodulation for the last thirty years. The somatotrope growth hormone (GH)/insulin-like growth fac-
tor-1 (IGF-1) axis in particular has been repeatedly shown to play a major regulatory role upon thymus function and T-cell 
development. This review will focus on the important thymotropic properties of the somatotrope GH/IGF-1 axis, and will 
try to discriminate these properties in function of the endocrine or paracrine/autocrine pathways involved in their media-
tion. Most importantly, in light of an increasing number of recent studies, GH and IGF-1 now appear as novel therapeutic 
agents that could be used for enhancing thymopoiesis in different cases of immune deficiencies, including aging-related 
immune dysfunction. 
Keywords: Thymus, growth hormone (GH), insulin-like growth factors (IGFs), HIV, growth hormone deficiency (GHD), Cha-
gas disease. 
GENERAL INTRODUCTION 
The thymus is now considered as a crucial organ for 
maintenance of immune system homeostasis and the central 
lymphoid organ where occurs the generation of self-tolerant 
and competent naive T cells, as well as self-antigen specific 
natural Treg cells [1, 2]. However, for a long time, the thy-
mus has been regarded as an endocrine gland. In addition, 
the thymus now appears as a privileged site where the endo-
crine and immune systems intimately interact.  
A permanent crosstalk exists between the neuroendocrine 
and immune systems [3-6]. In addition to the strong modula-
tion of immunity by glucocorticoids and sexual steroids, 
other hormones have been more and more involved in im-
munomodulation. Indeed, the somatotrope GH/IGF-1 axis, 
as well as prolactin and thyroid hormones [7], were shown to 
play an important regulatory role in T-cell development [8-
10].  
GH is mainly synthesised in the anterior pituitary gland 
but can also be produced by immune cells [11, 12]. GH has 
several biological actions in the immune system including 
regulation of thymopoiesis and T-cell development [13]. 
Nevertheless, it is uneasy to distinguish whether the thymo-
tropic effects of GH are direct or mediated by IGF-1, as most  
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of GH effects are driven by induction of IGF-1 and as IGF-1 
has also been described as an endogenous factor in the 
thymic microenvironment [12]. The evolution of the research 
field has brought new insights that justify an overview up-
date as some ancient conclusions about absence of GH re-
ceptor on human differentiating T cells, or the lack of effect 
of GH administration on human thymopoiesis, have been 
recently revisited. Finally, from the data of recent studies, it 
has been proposed that GH and IGF-1 could be novel thera-
peutic agents able to enhance thymopoiesis in immunodefi-
cient individuals [14-16]. 
The Thymus 
For a long time, the thymus function remained very ob-
scure. In 1961, Jacques F.A.P. Miller demonstrated the im-
portance of the thymus in the immune system by removing 
the thymus from three day-old mice, and observing thereaf-
ter the deficiency of a lymphocyte population, the thymus-
dependent lymphocytes or T lymphocytes [17]. Today, the 
thymus is still essentially considered as the organ responsible 
for the differentiation and the maturation of T cells, as well 
as of the natural Treg cells. 
Embryology of the Thymus 
In human embryogenesis, around 7 weeks, connections 
between the two parts of thymus gland and the pharynx dis-
appear and these 2 parts migrate to inferior and ventral posi-
tion to the developing thyroid. Then, they fuse to form a sin-
gle, bilobate thymus gland. The cortex and medulla become 
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well differentiated at 12 weeks. Shortly after, the thymus is 
infiltrated by lymphocytes derived from stem cells in the 
yolk sac, omentum and liver, and the organ reachs its final 
location in the anterior superior mediastinum in front of the 
heart, behind the sternum. In the 16th week, the thymus is 
fully developed. The thymus increases in size from birth, 
where it is highly active until puberty. At that time, the thy-
mus then undergoes a very slow involution, i.e. an age-
dependent progressive decrease of the thymus mass [18, 19]. 
During mouse embryogenesis, the thymus epithelium de-
rives from the single endodermal layer of the third pharyn-
geal pouch only. This process depends on interactions with 
the surrounding neural crest-derived mesenchyme and occurs 
between embryonic day (E) 10.5 and E11.5 [20, 21]. At more 
or less E12, lymphocyte progenitors colonized the immature 
thymus, which is, at this stage, mainly composed of thymic 
epithelial cells (TEC) progenitors without cortical and me-
dullary definition [22, 23]. Subsequently, TEC progenitors 
will differentiate and lead to the construction of distinct cor-
tical and medullary TEC subsets that are the major constitu-
ents of thymic stroma [23]. Maintaining TEC differentiation 
is influenced by thymocyte-derived signals [24]. This inter-
dependence of thymocyte and TEC populations has been 
called thymic crosstalk [25]. In addition to thymocytes, other 
non-hematopoietic stromal elements, such as fibroblasts and 
endothelial cells, and distinct bone marrow-derived dendritic 
cells (DC) and macrophages also contribute to the final 
thymic architecture [26]. Thymic mesenchymatous cells also 
contribute to various structures of the thymus such as cap-
sule or vasculature [27-30]. 
Thymic T-Cell Development 
Like all hematopoietic cells, T lymphocytes originate 
from bone-marrow-resident hematopoietic stem cells (HSC). 
HSC will generate all blood lineages within the marrow 
whereas T-cell development essentially takes place in the 
thymus. The thymus microenvironment is the unique organ 
that has the capacity to support T-lineage restriction and dif-
ferentiation [31]. T-cell precursors from fetal liver then bone 
marrow migrate to the thymus in small numbers through the 
blood vessels in the cortico-medullary junction. The course 
of these precursors through the thymus is schematized in the 
Fig. (1) with the principal differentiative events. At this mo-
ment, the immature thymocyte does not express surface 
molecules such as the T-cell receptor for antigen (TCR), 
which is responsible for recognizing antigens presented by 
 
Fig. (1). Stages of thymocyte differentiation: Pre-T cells entering the thymus express no CD8 and weakly CD4. They also lack CD25, but 
express CD44. They acquire CD25 while CD4 becomes undetectable. These DN cells begin to co-express CD4 and CD8 giving the unique 
thymic population of DP cells and activate the TCR rearrangement by expression of the RAG enzymes that first recombine the β locus of 
TCR genes. The non-productive rearrangement leads to cell death by apoptosis. Recombination by-products are the DJβTREC, followed by 
the VDβTREC (not shown in the diagram). A second phase of recombination concerns the a locus and begins with the excision follows. This 
phase begins by the excision of the δ locus and this excision circle is usually named sjTREC, while the last excision circles resulting from α 
locus productive rearrangement between the Vα and Jα regions are often called cjTREC (not shown in the diagram). The positive selection 
process of competent T cells starts in the cortex. At this stage some cells deviate to the lineage of natural regulatory T cells (nTreg, 
CD4+CD25+Foxp3+), a selection process that will continue throughout the late differentiation stages. At the same time, the pre-T cells leave 
the cortex and enter the thymus medulla and fully co-express CD4 and CD8. These DP cells with a complete TCR go through the positive 
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proteins of the major histocompatibility complex (MHC), or 
the cluster differentiation (CD) markers CD4 and CD8, 
which are co-receptors of TCR [32]. Other markers such as 
CD25, CD3 and CD44 are very useful to define stages of 
intrathymic T-cell differentiation. CD3 forms with TCR a 
multimolecular complex that promotes signal transduction 
pathways necessary for TCR-driven T-cell activation. CD25 
is the α-chain of the interleukin-2 (IL-2) receptor. The pro-
teoglycan CD44 is a receptor for hyaluronic acid, and to 
lesser extent for fibronectin and collagen. In addition to be 
CD4-CD8-TCR-, the immature thymocytes recently migrated 
in the thymus are also CD25-CD44-CD3-. During their dif-
ferentiation, these precursor cells first acquire CD44 on the 
cell membrane following by CD25, becoming CD44+CD25+, 
and then sequentially lose CD44 and CD25. They represent 
3-5% of total thymocytes. Thymocyte maturation then pro-
gresses with the acquisition of both CD4 and CD8 markers, 
generating the so-called CD4+CD8+ double-positive thymo-
cytes (DP). These cells are the most common in the thymus, 
and represent 75-85% of the whole thymocyte population in 
adult. At this stage, DP cells undergo TCR gene rearrange-
ment. In differentiation of αβ T cells, the TCR β-chain-
related genes first rearrange followed by the TCR α-chain 
genes. Thymocytes that do not undergo productive TCR 
gene rearrangements die by apoptosis. By contrast, those 
expressing productive TCR will be able to interact with en-
dogenous peptides presented by MHC proteins, expressed by 
thymic microenvironmental cells. This interaction is crucial 
for normal thymocyte differentiation and determines both 
positive and negative selection. Positively selected T cells 
escape from programmed cell death and become mature 
CD4+ or CD8+ single positive (SP) cells. These single posi-
tive cells represent 12-15% of total thymocytes and will 
leave the thymus to yield the large majority of the T-cell 
repertoire in the periphery. Thymic T cells bearing a TCR 
with high affinity for the complex MHC/self-peptides are 
negatively selected and die by apoptosis [26, 32]. Some 
CD4+ cells express CD25 and the transcription factor FoxP3 
that controls the differentiation of natural CD4+CD25+ Treg 
cells. In addition to CD25 and Foxp3, natural Treg cells ex-
press CTLA-4, GITR and lymphoid homing receptors such 
as CD103, CD62L. Natural Treg cells play a crucial role in 
central tolerance and in preventing autoimmune diseases by 
down regulating any expanded peripheral lymphocyte pool. 
Studies showed that they suppress the function of effector 
CD4+CD25- T cells, cytotoxic CD8+ T cells, NK cells and B 
cells. This suppression depends both on cell-contacts and on 
immunosuppressive cytokines such as TGF-ß and IL-10. 
Therefore, they are key regulators in the control of autoim-
munity [2, 33]. Intrathymic T-cell differentiation is sup-
ported by interaction between thymocytes and various com-
ponents of the thymic microenvironment including TEC, 
macrophages, dendritic cells, fibroblasts, and extracellular 
matrix components [26, 34]. Moreover, recent studies have 
shown that the cytokine IL-7 synthesized by TEC is crucial 
for supporting thymocyte differentiation [35]. 
Until 1995, the thymus function was thought to decline in 
adult. However, through quantification of T-cell receptor 
rearrangement excision circles (TREC), the adult thymus 
was shown to be active late in life for delivering mature na-
ïve T lymphocytes to the periphery [36-38]. During V(D)J 
rearrangement of the TCR, the recombination-activating 
(RAG) enzymes RAG1 and RAG2 recognize the recombina-
tion signal sequences (RSS) that flank the coding segments. 
TREC correspond to the circularised DNA located between 
the two RSS. Different types of TREC are generated such as 
signal-joint (sj) TREC and DJβ-TREC. These TREC are 
stable and not duplicated during mitosis and, therefore, are 
diluted out during peripheral proliferation. Thus, TREC rep-
resent a reliable technique to assess thymic output of naïve T 
cells [39-42]. For practical reasons, sjTREC are the most 
useful for the overall thymic output as they are formed in 
70% of αβ T cells, while the sj/Dβ TREC ratio reflects the 
level of intrathymic T cell proliferation. Other TREC are 
either too diverse to be easily measured, or generated in mi-
nor T-cell subsets [43]. 
The Somatotrope GH/IGF-1 Axis and Thymus Function 
in Rodents  
GH is a hormone that exerts its effects through binding to 
the GH receptor (GHR), a type 1 cytokine receptor [44], 
which is the first cloned member of this family and which 
shares a single transmembrane domain structure with other 
receptors including the prolactin receptor, and many other 
type 1 cytokine proteins [45]. The GH signal transduction is 
mediated by the activation of the Janus Kinase (JAK)/Signal 
Transducer and Activator of Transcription (STAT) pathway 
[46]. GH binding to the GHR causes receptor dimerization 
and leads to the activation of JAK2 tyrosine kinase. The ac-
tivity of JAK2 mediates many of the downstream responses 
to GH through phosphorylation/dimerization of STAT5, mi-
togen-activated protein (MAP) kinases, other kinase cas-
cades and molecules involved in metabolism like insulin 
receptor substrate 1 (IRS-1) [47, 48]. Factors like suppressor 
of cytokine signaling (SOCS) and the protein tyrosine phos-
phatase SHP-1 appear to play a role in the down regulation 
of signalling by GH and cytokines [49]. 
The somatotroph cells located in anterior pituitary gland 
secretes GH under the influence of growth hormone releas-
ing hormone (GHRH) and ghrelin, whereas somatostatin 
inhibits GH secretion [50-53]. Ghrelin is an endogenous 
ligand for the GH secretagogue receptor (GHS-R). It is 
mainly secreted from the stomach but also by other organs 
such as the brain, pituitary, placenta, ovaries, testes, kidneys, 
small intestine, pancreas and lungs, and fasting stimulates 
ghrelin secretion [52, 53]. GH is also produced in many ex-
trapituitary sites, including cells of the immune system [11, 
54]. Indeed, studies have demonstrated the presence of Gh 
mRNA and corresponding protein in rat thymocytes [55, 56], 
and GHRH stimulates Gh expression by these cells [57]. 
However, studies in dwarf mice have evidenced that GH 
expression by pre-T and mature T cells do not fully depend 
on Pit-1, which is the main transcription factor for Gh ex-
pression in the pituitary [58, 59]. Therefore, the regulation of 
GH secretion may not be the same in lymphocytes and in the 
endocrine system.  
In 1974, it was shown that GH is able to bind to thymo-
cytes [60]. GH receptor (GHR) expression in murine thymo-
cytes is particulary detected in the DN immature subset [61]. 
These data indicate that direct effects of GH on thymocytes 
might precede events related to the further selection of the T-
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cell repertoire. Additionally, in situ hybridization studies in 
the rat thymus revealed an epithelial labelling for Ghr 
mRNA [62]. These findings suggest that GH exerts local 
paracrine/autocrine actions that may be direct or mediated by 
circulating IGF-1 or by other factors. Therefore, although the 
functions of GH and IGF-1 do not overlap entirely, many 
GH effects on multiple organs including the thymus and the 
peripheral immune system could also be mediated through 
IGF-1 induction. IGF-1 is part of the IGF system, which also 
includes IGF-2, insulin, six characterized binding proteins 
(IGFBP-1 through -6) and cell surface receptors that mediate 
the actions of the ligands (IGF type 1 receptor, insulin recep-
tor, and the IGF type 2 mannose-6-phosphate receptor) [63-
65]. The IGF type 1 receptor (IGF-1R) is a tyrosine kinase 
receptor, related to the insulin receptor [66]. The two major 
pathways activated by the IGF-1R are the MAPK and phos-
phatidylinositol 3-kinases (PI3-K) pathways [66]. An end-
point of the MAPK pathway is modification of transcription 
factor activity, such as activation of an ETS-like transcrip-
tion factor. Serum response factor (SRF) and activator pro-
tein 1 (AP-1) contribute to mitogenic signalling by many 
factors. Phosphorylation of IRS-1 is also involved in IGF-1 
signalling, similar to insulin signalling [67]. 
IGF-1 and -2 are growth-promoting factors regulating 
cellular survival, proliferation and differentiation [68]. Large 
amounts of IGF-1 and IGF-2 are present in blood of fetal 
rodents whereas, in adult rodents, their concentrations are 
low [69]. In mouse, in combination with GH, IGF accounts 
for 83% of postnatal body growth [70]. The cellular re-
sponses to both IGF-1 and IGF-2 are mediated by the IGF-
1R, and IGF biodisponibility is regulated by the IGF binding 
proteins [71]. IGF-1 is mainly produced in the liver and par-
ticipates in the regulation of GH secretion by the pituitary 
[68, 72]. Several studies have shown that murine TEC also 
express IGF-1 and IGF-1R. In mice, IGF-2 is the dominant 
thymic member of the family expressed in the thymus during 
fetal life, while IGF-1 predominates in postnatal [73, and 
personal observations]. IGF-1R has also been identified on 
rodent thymocytes [74]. In murine fetal thymic organ cul-
tures, inhibition of IGF-1 by a specific antibody resulted in 
significant changes in total thymocyte number and subset 
composition [73]. IGF-1 has also been proposed as a positive 
thymic regulator based on early observations that age-related 
thymic involution parallels the decrease in plasma IGF-1 
concentrations [75]. At the level of the whole organ, in vivo 
observations revealed that recombinant GH and IGF-1 accel-
erates the recovery of T cells after treatment with cy-
closporin A, which causes thymic atrophy, and that IGF-1 is 
able to induce repopulation of the atrophic thymus [76]. GH 
is supposed to initiate or to enhance a functional intrathymic 
circuitry including IGF-1 and its receptor. Administration of 
IGF-1 enhances the recovery of DP T cells in thymus after 
dexamethasone treatment in rats [77]. Therefore, IGF-1 is 
able to directly increase thymic cellularity. Implantation of 
GH3 cells in aged rats and recombinant IGF-1 supplementa-
tion in mice with impaired immune status leads to the recov-
ery of thymic atrophy [77, 78]. These data may also suggest 
that IGF-1 is produced by a variety of thymic cells in a 
paracrine/autocrine fashion independently of GH regulation. 
It has also been shown that administration of rhIGF-1 in 
mice for one to two weeks results in an increase of thymic 
mass by doubling T-lymphocyte population [79]. This is 
further evidence showing that treatment with rhIGF-1 in-
creases thymocyte number. Furthermore, in restoration of the 
thymus, GH is less effective than IGF-1 but the best results 
are obtained by combination therapy [80]. Recently, it has 
been evidenced that, in intact thymus, IGF-1 increases pe-
ripheral naive and recent thymic emigrant (RTE) whereas, in 
IGF-1-treated thymectomized mice, no changes were ob-
served in the peripheral T-cell population, suggesting that 
IGF-1 increases thymic function and thymic output through a 
sequential increase in thymocyte subset proliferation [81]. A 
recent study has also demonstrated the importance of 
IGFBP-4 in thymic development since Igfbp4 transgenic 
mice show a significantly reduced thymus [82]. 
The first evidence showing that GH is involved in thymic 
regulation was the involution of the rat thymus observed 
following hypophysectomy [8]. Then, other studies have 
confirmed this observation and converging data now firmly 
indicate that IGF-1 is involved in the effects of GH in the 
thymus. GH/IGF-1 could act on numerous thymic functions. 
Different studies on rodents have shown that the somatotrope 
axis act on thymocyte number [83, 84], on TEC growth [85, 
86] and on the production by TEC of the chemokines 
CXCL12 and CCL25 [87, 88]. 
Effects on Thymocyte Number 
Besides the effect of GH/IGF-1 on thymocytes, several 
studies evidenced that GH can modulate proliferation of 
lymphoid precursors in the bone marrow, therefore increas-
ing the number of potential pre-T cells that will differentiate 
into the thymus. GH has also been shown to influence hema-
topoiesis. In vitro, GH directly enhances erythropoiesis [89] 
and a decrease in splenic hematopoietic progenitor cells is 
observed in GH-deficient dwarf mice [90]. In addition, GH 
has been shown to indirectly stimulate granulopoiesis in vi-
tro through the release of secondary mediators such as IGF-1 
[91]. In vivo, GH exerts significant direct hematopoietic 
growth-promoting effects and partially counteracts the mye-
losuppressive effects of azydothymidine [92]. A direct effect 
of GH on thymocytes is postulated since these cells ex-
pressed both GHR and IGF-1R [61, 74]. The exact mecha-
nism is not yet known, but it has been shown that GH en-
hances T-cell proliferation in rodents. The implantation in 
aged rats of pituitary GH3 cells secreting GH increases the 
size of their thymus and increases thymocyte numbers [79]. 
In GH- and prolactin-deficient dwarf DW/J mice, GH ad-
ministration increases thymic cell number and T-cell prolif-
eration [93]. Furthermore, multiple studies in snell dwarf 
mice have suggested that GH production by the pituitary 
gland also occurs during the stress response and that GH 
and/or IGF-1 might act as antagonists to glucocorticoids 
[94]. 
Effects on Thymic Epithelium 
TEC are essential to support T-cell differentiation and se-
lection. A recent study has demonstrated that, in mice, IGF-1 
administration leads to an increase of cTEC and mTEC 
numbers and also to an increase in thymocyte number and 
proliferation [83]. In addition, IGF-1 stimulates the produc-
tion of CXCL12 and CCL25 by TEC, which are chemokines 
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with an essential role in thymocyte development by regulat-
ing directional migration and thymic homing of developing 
thymocytes [83]. Expanded number of TEC results in in-
creased levels of extracellular matrix elements such as 
laminin that are important for thymocyte adherence. Under 
isogenic and xenogenic conditions, GH plays a role in the 
recirculation of T lymphocytes. Indeed, recombinant human 
GH promotes human T-cell transplantation in SCID mice 
and the murine thymus is colonized by human T cells. This 
process is thought to be mediated by adhesion molecules and 
by the extracellular matrix [95]. Furthermore, addition of GH 
or IGF-1 in murine TEC cultures increases production of 
fibronectin and laminin but also enhances expression of their 
receptors, VLA-5 and VLA-6, which leads to an increase of 
thymocyte adhesion to cultured TEC [96, 97]. Finally, a 
study has also demonstrated by in vivo and in vitro (fetal 
thymic organ cultures) manipulations that IGF-1 stimulates 
the entrance of T-cell precursors into the thymus [98]. 
Effects on Cytokines 
In addition, other findings strongly suggest that GH also 
influences cytokine production by the thymic microenviron-
ment. Increased cytokine production such as IL-1α, IL-1β 
and IL-6 due to exogenous GH was first demonstrated in 
bovine thymic stromal cells [99]. IL-6 production by thymo-
cytes is also upregulated by in vivo injection of GH in ageing 
animals [100]. In addition, in vivo injection of GH in ageing 
animals significantly increases thymulin levels [100]. These 
enhancing effects of GH on thymulin secretion were directly 
obtained by treating murine or human primary TEC cultures 
[87]. These data point to a direct effect of GH upon TEC, 
improving thymulin production. 
Altogether, these data argue for an important role of the 
GH/IGF-1 axis in regulating normal thymus function and T-
cell development even if they are not essential for normal 
thymus and T cell function [101]. 
The Somatotrope GH/IGF-1 Axis and Thymus Function 
in Humans 
Besides strong evidence that the somatotrope GH/IGF-1 
axis affects thymus physiology in animals, several studies 
led to the same conclusions in humans. Indeed, several stud-
ies have shown that GH exerts thymotropic properties in 
humans, which are either direct or mediated by IGF-1 [102]. 
In humans, GH is produced by extra-pituitary sites, including 
TEC, thymocytes, and peripheral lymphocytes [11, 54, 103]. 
Initially, via immunocytochemistry and in situ hybridization 
experiments, intrathymic production of GH has been re-
vealed in cTEC, in septal cells but not in thymocytes [56]. 
Nonetheless, several other studies have demonstrated that 
immunoreactive and biologically GH is produced by isolated 
human thymocytes [85]. More recently, by RT-PCR and 
immunoradiometric assays, GH was shown to be produced 
and secreted by isolated human thymocytes, as well as by 
human TEC primary cultures [104]. Like in rodents, the 
regulation of GH secretion in lymphocytes differs from the 
one in the pituitary. Indeed, exogenous IGF-1 did not affect 
GH secretion by human lymphocytes, while exogenous hGH 
was demonstrated to up-regulate hGH secretion in vitro 
[105]. The biological effects of GH are mediated by recep-
tors located in target cells membranes. The binding of GH 
causes dimerization of its receptor with activation of JAK2 
and STAT5 proteins, which is comparable to GH signalling 
in mice [106]. GHR is expressed by human thymocytes, and 
this expression is mainly present in immature CD34+CD2+ 
CD3-CD4-CD8- triple negative precursors, which display 
various capacities for differentiation [62]. This finding is in 
agreement with GHR expression by immature murine thymic 
cell subsets. However, GHR can also be seen in a minor per-
centage of mature thymocytes, thus suggesting that GH may 
act throughout the whole differentiation process [107]. Fig. 
(2) presents a summarized view of the GHR expression 
along the differentiating T cells. Together, these data support 
a paracrine/autocrine mode of action for GH in the human 
thymus although the effects of GH might be partially medi-
ated by IGF-1. 
Unlike in rodents, IGF-1 and IGF-2 plasma concentra-
tions are high in adult humans [69, 108]. Little information is 
available about the variation of their thymic expression dur-
ing ontogeny, IGF-1 is weakly expressed in TEC after birth 
[109]. Therefore, the involvement of IGF-1 in the human 
thymus might differ from the observations in the mouse 
model. Contrary to IGF-2, IGF-1 plasma concentrations are 
controlled by GH status [69]. However, some amounts of 
IGF-1 are also regulated by GH-independent pathways, as 
evidenced by the presence of significant plasma IGF-1 levels 
in GHR-deficient humans [110]. In addition to being mainly 
secreted by the liver and other tissues, there are ample evi-
dence for a local production of IGF-1 in the thymus where 
this growth factor could act in an autocrine/paracrine way. 
Receptor activation following binding of IGF-1 and IGF-2 
elicits a repertoire of cellular responses including prolifera-
tion, and protection of cells from programmed cell death or 
apoptosis. The two best-characterized pathways associated 
with IGF-1R activation are the MAPK and PI3-K pathways 
[111]. The expression of IGF-1 and IGF-1R by thymic T 
cells has been suggested, since anti-IGF-1R antibodies can 
block IGF-1 effects on these cells [87, 101]. Later, it has 
been shown that, in the human thymus, DN thymocytes have 
the highest level of IGF-1R expression, followed by DP 
cells, whereas the SP thymocytes express the lowest number 
of IGF-1R [104]. As for GHR, IGF-1R presence according 
to differentiation steps of T cells is represented in Fig. (2). 
Moreover, the presence of IGF-1R in human TEC has been 
characterized and IGF-1 stimulates expression of laminin, 
fibronectin, VLA-5 and VLA-6 by these cells, thus demon-
strating the functionality of IGF-1R in human TEC [112]. 
Like in rodents, several studies have shown that GH/IGF-1 
axis exerts its effects on numerous thymic functions such as 
the proliferation of thymocytes, TEC growth, and TEC pro-
duction of chemokines like CXCL12 and CCL25. 
Effects on Thymocyte Number 
In humans, GH and IGF-1 have also been shown to exert 
an impact on hematopoiesis. Administration of IGF-1 in pa-
tients suffering from Laron syndrome (with GHR deficiency) 
results in a strong stimulatory effect on erythropoiesis [113]. 
Accordingly, erythropoiesis, which is impaired in adult GH-
deficiency, is stimulated once the patients undergo GH 
treatment [114]. Therefore, an effect on pre-T cell number 
has to be considered, in addition to the potential direct action 
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on thymus function. Long-term GH treatment of immunode-
ficient HIV-infected patients leads to increase in thymic 
mass, in frequency of circulating TREC within PBMC, and 
in the number of CD4+ T cells [15]. These findings are con-
sistent with animal studies showing that GH is able to stimu-
late thymopoiesis. Furthermore, these increases of TREC 
frequency and T-cell gain are correlated to an increase of 
plasma IGF-1 [15], arguing for a crucial role of IGF-1 in 
GH-mediated stimulation of thymic T-cell production. Inves-
tigation of thymopoiesis in adult GH deficiency (AGHD) has 
demonstrated that, after GH withdrawal, intrathymic T-cell 
proliferation and thymic T-cell output decreased whereas 
resumption of GH treatment led to an increase of thymopoie-
sis to a level close to the one before withdrawal of GH 
treatment [16]. Again, in this study, the close correlation 
between plasma IGF-1 concentrations and the frequency of 
sjTREC in PBMC suggests that the thymotropic properties 
of GH could be mediated by IGF-1 [16]. It should be also 
noted that the effects of the somatotrope GH/IGF-1 axis on 
thymocytes might be relayed by other soluble factors like 
cytokines. Among them, IL-7 is a cytokine essential for 
V(D)J recombination at the TCR locus, and this cytokine 
modulates chromatin accessibility for RAG-mediated cleav-
age. IL-7 is the only known interleukin that promotes T-cell 
differentiation and so appears to be a candidate in mediating 
GH/IGF-1 actions upon the thymus [115, 116]. 
Effects on Thymic Epithelium 
An increase in thymic tissue was observed in HIV-
infected adults after GH therapy [14]. These data are consis-
tent with previous studies documenting the ability of GH to 
stimulate thymopoiesis in animals and establishes that GH 
also has significant effects on the human immune system. 
Although the effect on thymic epithelium was not directly 
investigated, it confirms that GH/IGF-1 axis induces thymo-
tropic properties as shown by thymic hyperplasia detected in 
acromegaly patients [117]. 
PHARMACOLOGICAL IMPLICATIONS 
Implications in Immunosenescence 
Immune defences decline with age as evidenced by the 
increase of infections in elderly. After puberty and with ad-
vancing age, the thymic space becomes progressively filled 
with adipocytes coupled with a dramatic loss of thymocytes 
leading to a reduction in output of naïve T cells. This process 
is called thymic adipose involution [56]. The age-related 
decline in immune functions (immunosenescence, which 
includes the skewing of CD4/CD8 ratio toward CD8) is par-
tially responsible for the increased prevalence and severity of 
infectious diseases, and the low efficiency of vaccination in 
elderly persons [118, 119]. There has been considerable in-
 
Fig. (2). GHR and IGF-1R expression: The proliferation and differentiation effect can be differently marked depending on the stage of cell 
differentiation in the thymus. The size bars reflects the abundance of GH and IGF-1 receptors found on T cell subsets. The pre-T cells during 
DN stages present the highest level of both GHR and IGF-1R. The proliferation stage where the TCR rearrangement occurs ends with the 
generation of numerous DP cells with a complete TCR. These cells bear little or no GHR, while IGF-1R were clearly found on rodent cells, 
but were decreased on human DP cells. Differentiiaon ends with the SP cells with GHR reappearing, mostly on the CD4 subset, and IGF-1R 
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terest in using hormone replacement therapy to regenerate 
the involuted thymus during aging. The possibility that the 
GH/IGF-1 axis improves thymic functions, including thymo-
cyte proliferation and migration, particularly places these 
molecules as potential therapeutic agents. Indeed, implanta-
tion of GH-producing cells in old rats reverses thymus atro-
phy [78], and further studies have demonstrated that GH 
treatment increased thymic cellularity in aged animals. Con-
sistent results were also obtained with IGF-1 administration. 
In old animals, enhancement of thymopoiesis was also 
achieved with IGF-1 [77]. Although GH and IGF-1 increase 
thymopoiesis in old animals, it is important to note that T-
cell production is not restored to the level present in young 
animals suggesting that there may be limits on the extent to 
which GH and IGF-1 can improve thymopoiesis in old ro-
dents [98]. Interestingly, treatment of SCID mice with a GH 
secretagogue (GHS) results in increased thymic cellularity 
and differentiation, as well as in promoting thymic engraft-
ment in bone marrow transplant [120]. Furthermore, ghrelin, 
a potent GH secretagogue, can also promote T-cell output 
from an aging thymus [121]. Also in primary immunodefi-
ciencies, manipulation of the somatotrope GH/IGF-1 axis 
offers promising results. As noted above, GH treatment of 
AGHD was shown to improve thymus function [16]. Con-
trary to AGHD however, the GH deficient child presents an 
intact immune function. So, in case of deficiency, GH could 
be replaced by other factors allowing a normal function of 
the immune system [122]. For example, ghrelin can exert 
GH-like properties at different levels of the immune function 
[123].  
Implications for HIV Infection 
The targeting of the thymus by HIV has been extensively 
studied. Complex interactions involving inflammatory infil-
trates surrounding lymphodepleted thymic epithelium [124], 
disrupted early T cell development [40] and increased 
thymic production of nTreg [125] are currently documented. 
Treatment of HIV infection treatment dramatically improved 
with highly active antiretroviral therapy (HAART). How-
ever, this therapy causes adverse events, which include 
metabolic changes termed lipodystrophy. Several mecha-
nisms are underlying lipodystrophy and HIV itself may have 
a role in its aetiology [126]. Lipodistrophy, which occurs in 
83% of HIV-infected patients with HAART, is associated 
with alterations in GH dynamics similar to what is observed 
in severe AGHD [127]. The idea that GH supplementation of 
these patients with lipodystrophy might improve the thymus-
driven reconstitution of CD4 compartment was therefore 
tested. Indeed, early studies on GH therapy in HIV patients 
had limited results. For example, Nguyen et al. have reported 
that administration of rhGH or rhIGF-1 to patients did not 
lead to a significant increase in CD4+ T cell numbers [128]. 
Later, through the use of increasingly widespread of the 
antiretroviral therapy, the observation of lipodystrophy and 
its associated GHD leads to discriminate between patients 
with HAART who are deficient in GH or not. The striking 
result was that CD4 count, thymus volume, plasmatic IL-7 
and RTE were all significantly lower in a group of HIV-
infected children with GHD versus GHD negative group 
[129]. Thereafter, it was shown that thymopoiesis as well as 
the numbers of CD4+ RTE cells were increased in middle-
aged AIDS patients treated with GH and antiretroviral ther-
apy [15, 130]. The conclusion is that, coupled to antiretrovi-
ral therapy and especially when a GHD is evidenced, GH 
could be effective to enhance the restoration of a full im-
mune response. 
Implications for Chagas Disease 
The effects of GH therapy are currently investigated in 
another infectious disease, Chagas disease, which is a debili-
tating inflammatory disease caused by the protozoan parasite 
Trypanosoma cruzi. In mice infected by T. cruzy, a thymus 
atrophy, including DP cell depletion [131], and a decrease in 
GH production are observed. Indeed, the thymus is a target 
for numerous infectious diseases including T. cruzi [132] and 
T. cruzi also affects the hypothalamo-pituitary axis in mice 
[133]. Demonstration that GH3 cells, a model of GH-
secreting cells, infected by T. cruzi have downregulated their 
Pit-1 expression, and consequently their GH expression, has 
recently been brought provided [134]. Lately, it was shown 
that treatment of infected mice with GH leads to a reduction 
in the number of blood trypomastigotes, as well as the car-
diac tissue parasitism and inflammatory infiltrate suggesting 
that GH therapy enhances the immune response [135]. In 
human, decreased CD4 lymphocytes in Chagas patients was 
described ten years ago [136]. Thymic function appears to be 
affected in several ways by T. cruzi, including the expression 
of chemokines, extracellular matrix molecules and receptors 
[137] and disturbing the pre-T cells trafficking, but also the 
shaping of peripheral T cell repertoire that reveals changes 
both in infected mice and human [138-140]. As for HAART-
treated HIV infection, conjonction of thymotropism of 
pathogen, GH/IGF-1 axis disturbance and correlated effects 
on T immune system suggest that GH can be considered as 
an immunomodulating substance for boosting the T-cell sys-
tem and controlling parasite replication, and a combination 
of GH with anti-infectious drugs could be a new therapeutic 
strategy to reduce the harmful effects of Chagas disease. 
However, it should be noted that GH increases CXCL12 
expression and pre-T cell migration [88], one of the 
chemokine augmented after T. cruzi infection with proposed 
negative consequences. Therefore, cautions must be taken 
before to concluding that GH treatment would always incre-
ment the benefit-cost ratio. 
Conclusions and Perspectives 
Accumulating data have evidenced that the hormones of 
the somatotrope axis, GH and IGF-1, are particularly in-
volved in the interaction between the two systems by en-
hancing thymus functions especially when they have been 
compromised by disease, therapy or aging as many studies 
have shown. It has been repeatedly shown that GH, IGF-1 
and their cognate receptors are expressed by immune cells, 
and that their thymotropic properties most probably involve 
also autocrine/paracrine mechanisms. Therefore, further in-
vestigations of the mechanisms involved in thymotropic ef-
fects of the GH/IGF-1 axis may shed light on the treatment 
and prevention of immunological disorders. From the obser-
vations resumed in this review, we can already conclude that, 
when a perturbation in GH/IGF-1 axis is clearly evidenced in 
immunodeficient individuals and when thymic function is, at 
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least partially, involved in the compromised immunity, the 
pharmacological use of GH deserves to be considered. 
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ABBREVIATIONS 
AGHD = Adult growth hormone deficiency 
CD = Cluster differentiation 
DN = Double-negative thymocytes 
DP = Double-positive thymocytes 
GH = Growth hormone 
GHD = Growth hormone deficiency 
HAART = Highly active antiretroviral therapy 
MHC = Major histocompatibility complex 
RAG = Recombination-activating enzymes 
RSS = Recombination signal sequences 
SP = Single positive T cells 
SjTREC = Signal-joint TREC 
TEC = Thymic epithelial cells 
TCR = T-cell receptor for antigen 
TREC = T-cell receptor rearrangement excision 
circles 
REFERENCES 
[1] Rothenberg, E.V.; Yui, M.A.; Telfer, J.C. T-Cell Developmental 
Biology. In: Fundamental Immunology 5th ed.; Paul, W.E. Ed.; 
Lippincott Williams & Wilkins; Philadelphia, 2003, pp. 259-301. 
[2] Liston, A.; Nutsch, K.M.; Farr, A.G.; Lund, J.M.; Rasmussen, J.P.; 
Koni, P.A.; Rudensky, A.Y. Differentiation of regulatory Foxp3+ T 
cells in the thymic cortex. Proc. Natl. Acad. Sci. USA, 2008, 
105(33), 11903-11908. 
[3] Blalock, J.E. The syntax of immune-neuroendocrine communica-
tion. Immunol. Today, 1994, 15(11), 504-511. 
[4] Savino, W.; Dardenne, M. Immune-neuroendocrine interactions. 
Immunol. Today, 1995, 16(7), 318-322. 
[5] Madden, K.S.; Felten, D.L. Experimental basis for neural-immune 
interactions. Physiol. Rev., 1995, 75(1), 77-106. 
[6] Besedovsky, H.O.; del Rey, A. Immune-neuro-endocrine interac-
tions: facts and hypotheses. Endocr. Rev., 1996, 17(1), 64-102. 
[7] Arpin, C.; Pihlgren, M.; Fraichard, A.; Aubert, D.; Samarut, J.; 
Chassande, O.; Marvel, J. Effects of T3R alpha 1 and T3R alpha 2 
gene deletion on T and B lymphocyte development. J. Immunol., 
2000, 164(1), 152-160. 
[8] Smith, P. The effect of hypophysectomy upon the involution of the 
thymus in the rat. Anat. Rec., 1930, 47, 119-143. 
[9] Weigent, D.A. Immunoregulatory properties of growth hormone 
and prolactin. Pharmacol. Ther., 1996, 69(3), 237-257. 
[10] Savino, W.; Dardenne, M. Pleiotropic modulation of thymic func-
tions by growth hormone: from physiology to therapy. Curr. Opin. 
Pharmacol., 2010, 10(4), 434-442. 
[11] Weigent, D.A.; Blalock, J.E. Expression of growth hormone by 
lymphocytes. Int. Rev. Immunol., 1989, 4(3), 193-211. 
[12] Venters, H.D.; Dantzer, R.; Freund, G.G.; Broussard, S.R., Kelley, 
K.W. Growth hormone and insulin-like growth factor as cytokines 
in the immune system. In Psychoneuroimmunology, 3rd ed.; Ader, 
R.; Felten, D.L. Cohen, N. Eds.; Academic Press, San Diego, 2001; 
Vol. 1, pp 339-362. 
[13] Meazza, C.; Pagani, S.; Travaglino, P.; Bozzola, M. Effect of 
growth hormone (GH) on the immune system. Pediatr. Endocrinol. 
Rev., 2004, (1 Suppl. 3), 490-495. 
[14] Napolitano, L.A.; Lo, J.C.; Gotway, M.B.; Mulligan, K.; Barbour, 
J.D.; Schmidt, D.; Grant, R.M.; Halvorsen, R.A.; Schambelan, M.; 
McCune, J.M. Increased thymic mass and circulating naive CD4 T 
cells in HIV-1-infected adults treated with growth hormone. AIDS, 
2002, 16(8), 1103-1111. 
[15] Napolitano, L.A.; Schmidt, D.; Gotway, M.B.; Ameli, N.; Filbert, 
E.L.; Ng, M.M.; Clor, J.L.; Epling, L.; Sinclair, E.; Baum, P.D.; Li, 
K.; Killian, M.L.; Bacchetti, P.; McCune, J.M. Growth hormone 
enhances thymic function in HIV-1-infected adults. J. Clin. Invest., 
2008, 118(3), 1085-1098. 
[16] Morrhaye, G.; Kermani, H.; Legros, J.J.; Baron, F.; Beguin, Y.; 
Moutschen, M.; Cheynier, R.; Martens, H.J.; Geenen, V. Impact of 
growth hormone (GH) deficiency and GH replacement upon thy-
mus function in adult patients. PLoS One, 2009, 4(5), e5668. 
[17] Miller, J.F., The discovery of thymus function and of thymus-
derived lymphocytes. Immunol. Rev., 2002, 185, 7-14. 
[18] Haynes, B.F.; Heinly, C.S. Early human T cell development: analy-
sis of the human thymus at the time of initial entry of hema-
topoietic stem cells into the fetal thymic microenvironment. J. Exp. 
Med., 1995, 181(4), 1445-1458. 
[19] Larsen, W.J. Development of the Head and Neck. In: Human Em-
bryology 1st ed.; Larsen, W.J. Ed.; Churchill Livingstone; New 
York, 1993, pp. 311-340. 
[20] Blackburn, C.C.; Manley, N.R. Developing a new paradigm for 
thymus organogenesis. Nat. Rev. Immunol., 2004, 4(4), 278-289. 
[21] Gordon, J.; Wilson, V.A.; Blair, N.F.; Sheridan, J.; Farley, A.; 
Wilson, L.; Manley, N.R.; Blackburn, C.C. Functional evidence for 
a single endodermal origin for the thymic epithelium. Nat. Immu-
nol., 2004, 5(5), 546-553. 
[22] Jotereau, F.; Heuze, F.; Salomon-Vie, V.; Gascan, H. Cell kinetics 
in the fetal mouse thymus: precursor cell input, proliferation, and 
emigration. J. Immunol., 1987, 138(4), 1026-1030. 
[23] Rossi, S.W.; Jenkinson, W.E.; Anderson, G.; Jenkinson, E.J. Clonal 
analysis reveals a common progenitor for thymic cortical and me-
dullary epithelium. Nature, 2006, 441(7096), 988-991. 
[24] Anderson, G.; Pongracz, J.; Parnell, S.; Jenkinson, E.J. Notch 
ligand-bearing thymic epithelial cells initiate and sustain Notch 
signaling in thymocytes independently of T cell receptor signaling. 
Eur. J. Immunol., 2001, 31(11), 3349-3354. 
[25] van Ewijk, W.; Shores, E.W.; Singer, A. Crosstalk in the mouse 
thymus. Immunol. Today, 1994, 15(5), 214-217. 
[26] Ciofani, M.; Zuniga-Pflucker, J.C. The thymus as an inductive site 
for T lymphopoiesis. Annu. Rev. Cell. Dev. Biol., 2007, 23, 463-
493. 
[27] Muller, S.M.; Terszowski, G.; Blum, C.; Haller, C.; Anquez, V.; 
Kuschert, S.; Carmeliet, P.; Augustin, H.G.; Rodewald, H.R. Gene 
targeting of VEGF-A in thymus epithelium disrupts thymus blood 
vessel architecture. Proc. Natl. Acad. Sci. USA, 2005, 102(30), 
10587-10592. 
[28] Gray, D.H.; Tull, D.; Ueno, T.; Seach, N.; Classon, B.J.; Chidgey, 
A.; McConville, M.J.; Boyd, R.L. A unique thymic fibroblast popu-
lation revealed by the monoclonal antibody MTS-15. J. Immunol., 
2007, 178(8), 4956-4965. 
[29] Raviola, E.; Karnovsky, M.J. Evidence for a blood-thymus barrier 
using electron-opaque tracers. J. Exp. Med., 1972, 136(3), 466-498. 
[30] Anderson, M.; Anderson, S.K.; Farr, A.G. Thymic vasculature: 
organizer of the medullary epithelial compartment? Int. Immunol., 
2000, 12(7), 1105-1110. 
[31] Scollay, R.; Smith, J.; Stauffer, V. Dynamics of early T cells: 
prothymocyte migration and proliferation in the adult mouse thy-
mus. Immunol. Rev., 1986, 91, 129-157. 
[32] MacDonald, H.R.; Howe, R.C.; Pedrazzini, T.; Lees, R.K.; Budd, 
R.C.; Schneider, R.; Liao, N.S.; Zinkernagel, R.M.; Louis, J.A.; 
Raulet, D.H.; Hengartner, H.; Miescher, G. T-cell lineages, reper-
toire selection and tolerance induction. Immunol. Rev., 1988, 104, 
157-182. 
18    Immun., Endoc. & Metab. Agents in Med. Chem., 2011, Vol. 11, No. 1 Goffinet et al. 
[33] Jiang, S.; Lechler, R.I.; He, X.S.; Huang, J.F. Regulatory T cells 
and transplantation tolerance. Hum. Immunol., 2006, 67(10), 765-
776. 
[34] Savino, W.; Mendes-da-Cruz, D.A.; Silva, J.S.; Dardenne, M.; 
Cotta-de-Almeida, V. Intrathymic T-cell migration: a combinatorial 
interplay of extracellular matrix and chemokines? Trends Immu-
nol., 2002, 23(6), 305-313. 
[35] Park, J.H.; Adoro, S.; Guinter, T.; Erman, B.; Alag, A.S.; Catal-
famo, M.; Kimura, M.Y.; Cui, Y.; Lucas, P.J.; Gress, R.E.; Kubo, 
M.; Hennighausen, L.; Feigenbaum, L.; Singer, A. Signaling by in-
trathymic cytokines, not T cell antigen receptors, specifies CD8 
lineage choice and promotes the differentiation of cytotoxic-lineage 
T cells. Nat. Immunol., 2010, 11(3), 257-264. 
[36] Douek, D.C.; McFarland, R.D.; Keiser, P.H.; Gage, E.A.; Massey, 
J.M.; Haynes, B.F.; Polis, M.A.; Haase, A.T.; Feinberg, M.B.; Sul-
livan, J.L.; Jamieson, B.D.; Zack, J.A.; Picker, L.J.; Koup, R.A. 
Changes in thymic function with age and during the treatment of 
HIV infection. Nature, 1998, 396(6712), 690-695. 
[37] Poulin, J.F.; Viswanathan, M.N.; Harris, J.M.; Komanduri, K.V.; 
Wieder, E.; Ringuette, N.; Jenkins, M.; McCune, J.M.; Sekaly, R.P. 
Direct evidence for thymic function in adult humans. J. Exp. Med., 
1999, 190(4), 479-486. 
[38] Castermans, E.; Baron, F.; Willems, E.; Schaaf-Lafontaine, N.; 
Meuris, N.; Gothot, A.; Vanbellighen, J.F.; Herens, C.; Seidel, L.; 
Geenen, V.; Cheynier, R.; Beguin, Y. Evidence for neo-generation 
of T cells by the thymus after non-myeloablative conditioning. 
Haematologica, 2008, 93(2), 240-247. 
[39] Geenen, V.; Poulin, J.F.; Dion, M.L.; Martens, H.; Castermans, E.; 
Hansenne, I.; Moutschen, M.; Sekaly, R.P.; Cheynier, R. Quantifi-
cation of T cell receptor rearrangement excision circles to estimate 
thymic function: an important new tool for endocrine-immune 
physiology. J. Endocrinol., 2003, 176(3), 305-311. 
[40] Dion, M.L.; Poulin, J.F.; Bordi, R.; Sylvestre, M.; Corsini, R.; 
Kettaf, N.; Dalloul, A.; Boulassel, M.R.; Debre, P.; Routy, J.P.; 
Grossman, Z.; Sekaly, R.P.; Cheynier, R. HIV infection rapidly in-
duces and maintains a substantial suppression of thymocyte prolif-
eration. Immunity, 2004, 21(6), 757-768. 
[41] van den Dool, C.; de Boer, R.J. The effects of age, thymectomy, 
and HIV Infection on alpha and beta TCR excision circles in naive 
T cells. J. Immunol., 2006, 177(7), 4391-4401. 
[42] Dulude, G.; Cheynier, R.; Gauchat, D.; Abdallah, A.; Kettaf, N.; 
Sekaly, R.P.; Gratton, S. The magnitude of thymic output is geneti-
cally determined through controlled intrathymic precursor T cell 
proliferation. J. Immunol., 2008, 181(11), 7818-7824. 
[43] Dion, M.L.; Sekaly, R.P.; Cheynier, R. Estimating thymic function 
through quantification of T-cell receptor excision circles. Methods 
Mol. Biol., 2007, 380, 197-213. 
[44] Leonard, W.J. Type 1 Cytokines and Interferons and Their Recep-
tor. In: Fundamental Immunology 5th ed.; Paul, W.E. Ed.; Lippin-
cott Williams & Wilkins; Philadelphia, 2003, pp. 701-747. 
[45] Cosman, D.; Lyman, S.D.; Idzerda, R.L.; Beckmann, M.P.; Park, 
L.S.; Goodwin, R.G.; March, C.J. A new cytokine receptor super-
family. Trends Biochem. Sci., 1990, 15(7), 265-270. 
[46] Heim, M.H. The Jak-STAT pathway: cytokine signalling from the 
receptor to the nucleus. J. Recept. Signal Transduct. Res., 1999, 
19(1-4), 75-120. 
[47] Tripathi, A.; Sodhi, A. Growth hormone-induced production of 
cytokines in murine peritoneal macrophages in vitro: role of 
JAK/STAT, PI3K, PKC and MAP kinases. Immunobiology, 2009, 
214(6), 430-440. 
[48] Wang, X.; Yang, N.; Deng, L.; Li, X.; Jiang, J.; Gan, Y.; Frank, 
S.J. Interruption of growth hormone signaling via SHC and ERK in 
3T3-F442A preadipocytes upon knockdown of insulin receptor 
substrate-1. Mol. Endocrinol., 2009, 23(4), 486-496. 
[49] Flores-Morales, A.; Greenhalgh, C.J.; Norstedt, G.; Rico-Bautista, 
E. Negative regulation of growth hormone receptor signaling. Mol. 
Endocrinol., 2006, 20(2), 241-253. 
[50] Mayo, K.E.; Miller, T.L.; DeAlmeida, V.; Zheng, J.; Godfrey, P.A. 
The growth-hormone-releasing hormone receptor: signal transduc-
tion, gene expression, and physiological function in growth regula-
tion. Ann. NY Acad. Sci., 1996, 805, 184-203. 
[51] Tentler, J.J.; Hadcock, J.R.; Gutierrez-Hartmann, A. Somatostatin 
acts by inhibiting the cyclic 3',5'-adenosine monophosphate 
(cAMP)/protein kinase A pathway, cAMP response element-
binding protein (CREB) phosphorylation, and CREB transcription 
potency. Mol. Endocrinol., 1997, 11(7), 859-866. 
[52] van der Lely, A.J.; Tschop, M.; Heiman, M.L.; Ghigo, E. Biologi-
cal, physiological, pathophysiological, and pharmacological aspects 
of ghrelin. Endocr. Rev., 2004, 25(3), 426-457. 
[53] Kojima, M.; Kangawa, K. Ghrelin: structure and function. Physiol. 
Rev., 2005, 85(2), 495-522. 
[54] Chawla, R.K.; Parks, J.S.; Rudman, D. Structural variants of hu-
man growth hormone: biochemical, genetic, and clinical aspects. 
Annu. Rev. Med., 1983, 34, 519-547. 
[55] Maggiano, N.; Piantelli, M.; Ricci, R.; Larocca, L.M.; Capelli, A.; 
Ranelletti, F.O. Detection of growth hormone-producing cells in 
human thymus by immunohistochemistry and non-radioactive in 
situ hybridization. J. Histochem. Cytochem., 1994, 42(10), 1349-
1354. 
[56] Weigent, D.A.; Blalock, J.E. The production of growth hormone by 
subpopulations of rat mononuclear leukocytes. Cell. Immunol., 
1991, 135(1), 55-65. 
[57] Guarcello, V.; Weigent, D.A.; Blalock, J.E. Growth hormone re-
leasing hormone receptors on thymocytes and splenocytes from 
rats. Cell. Immunol., 1991, 136(2), 291-302. 
[58] Weigent, D.A.; Blalock, J.E. Effect of the administration of 
growth-hormone-producing lymphocytes on weight gain and im-
mune function in dwarf mice. Neuroimmunomodulation, 1994, 
1(1), 50-58. 
[59] Kooijman, R.; Malur, A.; Van Buul-Offers, S.C.; Hooghe-Peters, 
E.L. Growth hormone expression in murine bone marrow cells is 
independent of the pituitary transcription factor Pit-1. Endocrinol-
ogy, 1997, 138(9), 3949-3955. 
[60] Arrenbrecht, S. Specific binding of growth hormone to thymocytes. 
Nature, 1974, 252 (5480), 255-257. 
[61] Gagnerault, M.C.; Postel-Vinay, M.C.; Dardenne, M. Expression of 
growth hormone receptors in murine lymphoid cells analyzed by 
flow cytofluorometry. Endocrinology, 1996, 137(5), 1719-1726. 
[62] Mertani, H.C.; Morel, G. In situ gene expression of growth hor-
mone (GH) receptor and GH binding protein in adult male rat tis-
sues. Mol. Cell. Endocrinol., 1995, 109(1), 47-61. 
[63] Jones, J.I.; Clemmons, D.R. Insulin-like growth factors and their 
binding proteins: biological actions. Endocr. Rev., 1995, 16(1), 3-
34. 
[64] LeRoith, D.; Baserga, R.; Helman, L.; Roberts, C.T.Jr. Insulin-like 
growth factors and cancer. Ann. Intern. Med., 1995, 122(1), 54-59. 
[65] Nissley, P.; Lopaczynski, W. Insulin-like growth factor receptors. 
Growth Factors, 1991, 5(1), 29-43. 
[66] Adams, T.E.; Epa, V.C.; Garrett, T.P.; Ward, C.W. Structure and 
function of the type 1 insulin-like growth factor receptor. Cell. Mol. 
Life Sci., 2000, 57(7), 1050-1093. 
[67] Bu, Y.H.; He, Y.L.; Zhou, H.D.; Peng, D.; Liu, W.; Tang, A.G.; 
Tang, L.L.; Xie, H.; Huang, Q.X.; Luo, X.H.; Liao, E.Y. Insulin re-
ceptor substrate 1 regulates the cellular differentiation and the matrix 
metalloproteinase expression of preosteoblastic cells. J. Endocrinol., 
2010, 206(3), 271-277.  
[68] Stewart, C.E.; Rotwein, P. Growth, differentiation, and survival: 
multiple physiological functions for insulin-like growth factors. 
Physiol. Rev., 1996, 76(4), 1005-1026. 
[69] Daughaday, W.H.; Rotwein, P. Insulin-like growth factors I and II. 
Peptide, messenger ribonucleic acid and gene structures, serum, 
and tissue concentrations. Endocr. Rev., 1989, 10(1), 68-91. 
[70] Lupu, F.; Terwilliger, J.D.; Lee, K.; Segre, G.V.; Efstratiadis, A. 
Roles of growth hormone and insulin-like growth factor 1 in mouse 
postnatal growth. Dev. Biol., 2001, 229(1), 141-162. 
[71] Hwa, V.; Oh, Y.; Rosenfeld, R.G. The insulin-like growth factor-
binding protein (IGFBP) superfamily. Endocr. Rev., 1999, 20(6), 
761-787. 
[72] Yakar, S.; Liu, J.L.; Stannard, B.; Butler, A.; Accili, D.; Sauer, B.; 
LeRoith, D., Normal growth and development in the absence of 
hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA, 
1999, 96(13), 7324-7329. 
[73] Kecha, O.; Brilot, F.; Martens, H.; Franchimont, N.; Renard, C.; 
Greimers, R.; Defresne, M.P.; Winkler, R.; Geenen, V. Involve-
ment of insulin-like growth factors in early T cell development: a 
study using fetal thymic organ cultures. Endocrinology, 2000, 
141(3), 1209-1217. 
[74] Verland, S.; Gammeltoft, S. Functional receptors for insulin-like 
growth factors I and II in rat thymocytes and mouse thymoma cells. 
Mol. Cell. Endocrinol., 1989, 67(2-3), 207-216. 
[75] Kelley, K.W.; Meier, W.A.; Minshall, C.; Schacher, D.H.; Liu, Q.; 
VanHoy, R.; Burgess, W.; Dantzer, R. Insulin growth factor-I in-
Pharmacological Implications of GH/IGF-1 Axis on Thymus Functions Immun., Endoc. & Metab. Agents in Med. Chem., 2011, Vol. 11, No. 1    19 
hibits apoptosis in hematopoietic progenitor cells. Implications in 
thymic aging. Ann. NY Acad. Sci., 1998, 840, 518-524. 
[76] Beschorner, W.E.; Divic, J.; Pulido, H.; Yao, X.; Kenworthy, P.; 
Bruce, G. Enhancement of thymic recovery after cyclosporine by 
recombinant human growth hormone and insulin-like growth factor 
I. Transplantation, 1991, 52(5), 879-884. 
[77] Hinton, P.S.; Peterson, C.A.; Dahly, E.M.; Ney, D.M. IGF-I alters 
lymphocyte survival and regeneration in thymus and spleen after 
dexamethasone treatment. Am. J. Physiol., 1998, 274(4 Pt 2), 
R912-920. 
[78] Kelley, K.W.; Brief, S.; Westly, H.J.; Novakofski, J.; Bechtel, P.J.; 
Simon, J.; Walker, E.B. GH3 pituitary adenoma cells can reverse 
thymic aging in rats. Proc. Natl. Acad. Sci. USA, 1986, 83(15), 
5663-5667. 
[79] Clark, R.; Strasser, J.; McCabe, S.; Robbins, K.; Jardieu, P. Insulin-
like growth factor-1 stimulation of lymphopoiesis. J. Clin. Invest., 
1993, 92(2), 540-548. 
[80] van Buul-Offers, S.C.; Kooijman, R. The role of growth hormone 
and insulin-like growth factors in the immune system. Cell. Mol. 
Life Sci., 1998, 54(10), 1083-1094. 
[81] Chu, Y.W.; Schmitz, S.; Choudhury, B.; Telford, W.; Kapoor, V.; 
Garfield, S.; Howe, D.; Gress, R.E. Exogenous insulin-like growth 
factor 1 enhances thymopoiesis predominantly through thymic 
epithelial cell expansion. Blood, 2008, 112(7), 2836-2846. 
[82] Zhou, R.; Flaswinkel, H.; Schneider, M.R.; Lahm, H.; Hoeflich, A.; 
Wanke, R.; Wolf, E. Insulin-like growth factor-binding protein-4 
inhibits growth of the thymus in transgenic mice. J. Mol. Endocri-
nol., 2004, 32(2), 349-364. 
[83] Sabharwal, P.; Varma, S. Growth hormone synthesized and se-
creted by human thymocytes acts via insulin-like growth factor I as 
an autocrine and paracrine growth factor. J. Clin. Endocrinol. Me-
tab., 1996, 81(7), 2663-2669. 
[84] Yamada, M.; Hato, F.; Kinoshita, Y.; Tominaga, K.; Tsuji, Y. The 
indirect participation of growth hormone in the thymocyte prolif-
eration system. Cell Mol. Biol. (Noisy-le-grand), 1994, 40(2), 111-
121. 
[85] Timsit, J.; Savino, W.; Safieh, B.; Chanson, P.; Gagnerault, M.C.; 
Bach, J.F.; Dardenne, M. Growth hormone and insulin-like growth 
factor-I stimulate hormonal function and proliferation of thymic 
epithelial cells. J. Clin. Endocrinol. Metab., 1992, 75(1), 183-188. 
[86] Tsuji, Y.; Kinoshita, Y.; Hato, F.; Tominaga, K.; Yoshida, K. The 
in vitro proliferation of thymus epithelial cells stimulated with 
growth hormone and insulin-like growth factor-I. Cell Mol. Biol. 
(Noisy-le-grand), 1994, 40(8), 1135-1142. 
[87] Aiuti, A.; Tavian, M.; Cipponi, A.; Ficara, F.; Zappone, E.; Hoxie, 
J.; Peault, B.; Bordignon, C. Expression of CXCR4, the receptor 
for stromal cell-derived factor-1 on fetal and adult human lympho-
hematopoietic progenitors. Eur. J. Immunol., 1999, 29(6), 1823-
1831. 
[88] Smaniotto, S.; de Mello-Coelho, V.; Villa-Verde, D.M.; Pleau, 
J.M.; Postel-Vinay, M. C.; Dardenne, M.; Savino, W. Growth hor-
mone modulates thymocyte development in vivo through a com-
bined action of laminin and CXC chemokine ligand 12. Endocri-
nology, 2005, 146(7), 3005-3017. 
[89] Golde, D.W.; Bersch, N.; Li, C.H. Growth hormone: species-
specific stimulation of erythropoiesis in vitro. Science, 1977, 
196(4294), 1112-1113. 
[90] Duquesnoy, R.J.; Pedersen, G. Immunologic and hematologic 
deficiencies of the hypopituitary dwarf mouse. In: Immunologic 
Defects in Laboratory Animals; Gershwin, M.E., Merchant, B. 
Eds.; Plenum; New York, 1981, Vol. 1, pp 309-324. 
[91] Merchav, S.; Tatarsky, I.; Hochberg, Z. Enhancement of human 
granulopoiesis in vitro by biosynthetic insulin-like growth factor 
I/somatomedin C and human growth hormone. J. Clin. Invest., 
1988, 81(3), 791-797. 
[92] Murphy, W.J.; Tsarfaty, G.; Longo, D.L. Growth hormone exerts 
hematopoietic growth-promoting effects in vivo and partially coun-
teracts the myelosuppressive effects of azidothymidine. Blood, 
1992, 80(6), 1443-1447. 
[93] Murphy, W.J.; Durum, S. K.; Longo, D.L. Differential effects of 
growth hormone and prolactin on murine T cell development and 
function. J. Exp. Med., 1993, 178(1), 231-236. 
[94] Dorshkind, K.; Horseman, N.D., Anterior pituitary hormones, 
stress, and immune system homeostasis. Bioessays, 2001, 23(3), 
288-294. 
[95] Taub, D.D.; Tsarfaty, G.; Lloyd, A.R.; Durum, S.K.; Longo, D.L.; 
Murphy, W.J. Growth hormone promotes human T cell adhesion 
and migration to both human and murine matrix proteins in vitro 
and directly promotes xenogeneic engraftment. J. Clin. Invest., 
1994, 94(1), 293-300. 
[96] Savino, W.; de Mello-Coelho, V.; Dardenne, M. Control of the 
thymic microenvironment by growth hormone/insulin-like growth 
factor-I-mediated circuits. Neuroimmunomodulation, 1995, 2(6), 
313-318. 
[97] de Mello-Coelho, V.; Villa-Verde, D.M.; Dardenne, M.; Savino, 
W. Pituitary hormones modulate cell-cell interactions between 
thymocytes and thymic epithelial cells. J. Neuroimmunol., 1997, 
76(1-2), 39-49. 
[98] Montecino-Rodriguez, E.; Clark, R.; Dorshkind, K. Effects of 
insulin-like growth factor administration and bone marrow trans-
plantation on thymopoiesis in aged mice. Endocrinology, 1998, 
139(10), 4120-4126. 
[99] Tseng, Y.H.; Kessler, M.A.; Schuler, L.A. Regulation of interleu-
kin (IL)-1alpha, IL-1beta, and IL-6 expression by growth hormone 
and prolactin in bovine thymic stromal cells. Mol. Cell. Endocri-
nol., 1997, 128(1-2), 117-127. 
[100] Goya, R.G.; Gagnerault, M.C.; De Moraes, M.C.; Savino, W.; 
Dardenne, M. In vivo effects of growth hormone on thymus func-
tion in aging mice. Brain Behav. Immun., 1992, 6(4), 341-354. 
[101] Dorshkind, K.; Horseman, N.D. The roles of prolactin, growth 
hormone, insulin-like growth factor-I, and thyroid hormones in 
lymphocyte development and function: insights from genetic mod-
els of hormone and hormone receptor deficiency. Endocr. Rev., 
2000, 21(3), 292-312. 
[102] Auernhammer, C.J.; Strasburger, C.J. Effects of growth hormone 
and insulin-like growth factor I on the immune system. Eur. J. En-
docrinol., 1995, 133(6), 635-645. 
[103] de Mello-Coelho, V.; Gagnerault, M.C.; Souberbielle, J.C.; 
Strasburger, C.J.; Savino, W.; Dardenne, M.; Postel-Vinay, M.C. 
Growth hormone and its receptor are expressed in human thymic 
cells. Endocrinology, 1998, 139(9), 3837-3842. 
[104] Kooijman, R.; Scholtens, L.E.; Rijkers, G.T.; Zegers, B.J. Type I 
insulin-like growth factor receptor expression in different devel-
opmental stages of human thymocytes. J. Endocrinol., 1995, 
147(2), 203-209. 
[105] Baxter, J.B.; Blalock, J.E.; Weigent, D.A. Expression of im-
munoreactive growth hormone in leukocytes in vivo. J. Neuroim-
munol., 1991, 33(1), 43-54. 
[106] Han, Y.; Leaman, D.W.; Watling, D.; Rogers, N.C.; Groner, B.; 
Kerr, I.M.; Wood, W.I.; Stark, G.R. Participation of JAK and 
STAT proteins in growth hormone-induced signaling. J. Biol. 
Chem., 1996, 271(10), 5947-5952. 
[107] Savino, W.; Postel-Vinay, M.C.; Smaniotto, S.; Dardenne, M. The 
thymus gland: a target organ for growth hormone. Scand. J. Immu-
nol., 2002, 55(5), 442-452. 
[108] Froesch, E.R.; Hussain, M. Recombinant human insulin-like 
growth factor-I: a therapeutic challenge for diabetes mellitus. Dia-
betologia, 1994, 37(Suppl. 2), S179-185. 
[109] Kecha, O.; Martens, H.; Franchimont, N.; Achour, I.; Hazee-
Hagelstein, M.T.; Charlet-Renard, C.; Geenen, V.; Winkler, R. 
Characterization of the insulin-like growth factor axis in the human 
thymus. J. Neuroendocrinol., 1999, 11(6), 435-440. 
[110] Rosenfeld, R.G.; Rosenbloom, A.L.; Guevara-Aguirre, J. Growth 
hormone (GH) insensitivity due to primary GH receptor deficiency. 
Endocr. Rev., 1994, 15(3), 369-390. 
[111] Benini, S.; Manara, M.C.; Cerisano, V.; Perdichizzi, S.; Stram-
miello, R.; Serra, M.; Picci, P.; Scotlandi, K. Contribution of 
MEK/MAPK and PI3-K signaling pathway to the malignant behav-
ior of Ewing's sarcoma cells: therapeutic prospects. Int. J. Cancer, 
2004, 108(3), 358-366. 
[112] de Mello Coelho, V.; Villa-Verde, D.M.; Farias-de-Oliveira, D.A.; 
de Brito, J.M.; Dardenne, M.; Savino, W. Functional insulin-like 
growth factor-1/insulin-like growth factor-1 receptor-mediated cir-
cuit in human and murine thymic epithelial cells. Neuroendocri-
nology, 2002, 75(2), 139-150. 
[113] Sivan, B.; Lilos, P.; Laron, Z. Effects of insulin-like growth factor-I 
deficiency and replacement therapy on the hematopoietic system in 
patients with Laron syndrome (primary growth hormone insensitiv-
ity). J. Pediatr. Endocrinol. Metab., 2003, 16(4), 509-520. 
[114] Christ, E.R.; Cummings, M.H.; Westwood, N.B.; Sawyer, B.M.; 
Pearson, T.C.; Sonksen, P.H.; Russell-Jones, D.L. The importance 
20    Immun., Endoc. & Metab. Agents in Med. Chem., 2011, Vol. 11, No. 1 Goffinet et al. 
of growth hormone in the regulation of erythropoiesis, red cell 
mass, and plasma volume in adults with growth hormone defi-
ciency. J. Clin. Endocrinol. Metab., 1997, 82(9), 2985-2990. 
[115] Huang, J.; Durum, S.K.; Muegge, K. Cutting edge: histone acetyla-
tion and recombination at the TCR gamma locus follows IL-7 in-
duction. J. Immunol., 2001, 167(11), 6073-6077. 
[116] Aspinall, R. T cell development, ageing and Interleukin-7. Mech. 
Ageing Dev., 2006, 127(6), 572-578. 
[117] Bazzoni, N.; Ambrosi, B.; Arosio, M.; Barbareschi, M.; Losa, M.; 
Faglia, G. Acromegaly and thymic hyperplasia: a case report. J. 
Endocrinol. Invest., 1990, 13(11), 931-935. 
[118] Taub, D.D.; Longo, D.L. Insights into thymic aging and regenera-
tion. Immunol. Rev., 2005, 205, 72-93. 
[119] Pfister, G.; Savino, W. Can the immune system still be efficient in 
the elderly? An immunological and immunoendocrine therapeutic 
perspective. Neuroimmunomodulation, 2008, 15(4-6), 351-364. 
[120] Koo, G.C.; Huang, C.; Camacho, R.; Trainor, C.; Blake, J. T.; 
Sirotina-Meisher, A.; Schleim, K.D.; Wu, T.J.; Cheng, K.; Nar-
gund, R.; McKissick, G. Immune enhancing effect of a growth 
hormone secretagogue. J. Immunol., 2001, 166(6), 4195-4201. 
[121] Dixit, V.D.; Yang, H.; Sun, Y.; Weeraratna, A.T.; Youm, Y.H.; 
Smith, R.G.; Taub, D.D. Ghrelin promotes thymopoiesis during ag-
ing. J. Clin. Invest., 2007, 117(10), 2778-2790. 
[122] Spadoni, G.L.; Rossi, P.; Ragno, W.; Galli, E.; Cianfarani, S.; 
Galasso, C.; Boscherini, B. Immune function in growth hormone-
deficient children treated with biosynthetic growth hormone. Acta 
Paediatr. Scand., 1991, 80(1), 75-79. 
[123] Dixit, V.D.; Schaffer, E.M.; Pyle, R.S.; Collins, G.D.; Sakthivel, 
S.K.; Palaniappan, R.; Lillard, J.W. Jr.; Taub, D.D. Ghrelin inhibits 
leptin- and activation-induced proinflammatory cytokine expres-
sion by human monocytes and T cells. J. Clin. Invest., 2004, 
114(1), 57-66. 
[124] Haynes, B.F.; Hale, L.P.; Weinhold, K.J., Patel, D.D.; Liao, H.X.; 
Bressler, P.B.; Jones, D.M.; Demarest, J.F.; Gebhard-Mitchell, K. 
Haase, A.T.; Bartlett, J.A. Analysis of the adult thymus in reconsti-
tution of T lymphocytes in HIV-1 infection. J. Clin. Invest., 1999 
103(4), 453-460. 
[125] Bandera, A.; Ferrario, G.; Saresella, M.; Marventano, I.; Soria, A.; 
Zanini, F.; Sabbatini, F.; Airoldi, M.; Marchetti, G.; Franzetti, F.; 
Trabattoni, D.; Clerici, M.; Gori, A. CD4+ T cell depletion, im-
mune activation and increased production of regulatory T cells in 
the thymus of hiv-infected individuals. PLoS One, 2010, 5, e10788. 
[126] Mallewa, J.E.; Wilkins, E.; Vilar, J.; Mallewa, M.; Doran, D.; 
Back, D.; Pirmohamed, M. HIV-associated lipodystrophy: A re-
view of underlying mechanisms and therapeutic options. J. Antimi-
crob. Chemother., 2008, 62(4), 648-660. 
[127] Zirilli, L.; Orlando, G.; Diazzi, C.; Squillace, N.; Carani, C.; Guar-
aldi, G.; Rochira, V. Hypopituitarism and hiv-infection: A new 
comorbidity in the HAART era? J. Endocrinol. Invest., 2008, 
31(9s), 33-38. 
[128] Nguyen, B.Y.; Clerici, M.; Venzon, D.J.; Bauza, S.; Murphy, W.J.; 
Longo, D.L.; Baseler, M.; Gesundheit, N.; Broder, S.; Shearer, G.; 
Yarchoan, R. Pilot study of the immunologic effects of recombi-
nant human growth hormone and recombinant insulin-like growth 
factor in HIV-infected patients. AIDS, 1998, 12(8), 895-904. 
[129] Vigano, A.; Saresella, M.; Trabattoni, D.; Giacomet, V.; di Natale, 
B.; Merlo, M.; Venuto, A.; Villa, M.L.; Vanzulli, S.; Ferrante, P. 
Clerici, M. Growth hormone in T-lymphocyte thymic and post-
thymic development: A study in HIV-infected children. J. Pediatr., 
2004, 145(4), 542-548. 
[130] Redelman, D.; Welniak, L.A.; Taub, D.; Murphy, W.J. Neuroendo-
crine hormones such as growth hormone and prolactin are integral 
members of the immunological cytokine network. Cell. Immunol., 
2008, 252(1-2), 111-121. 
[131] Verinaud, L.; Da Cruz-Hofling, M.A. Sakurada, J.K.; Rangel, 
H.A.; Vassallo, J.; Wakelin, D.; Sewell, H.F.; Camargo, I.J. Immu-
nodepression induced by trypanosoma cruzi and mouse hepatitis vi-
rus type 3 is associated with thymus apoptosis. Clin. Diagn. Lab. 
Immunol., 1998, 5(2), 186-191. 
[132] Savino, W. The thymus is a common organ target for infectious 
diseases. PLoS Pathog., 2006, 2, e62. 
[133] Correa-de-Santana, E.; Paez-Pereda, M.; Theodoropoulou, M.; 
Kenji Nihei, O.; Gruebler, Y.; Bozza, M.; Arzt. E.; Villa-Verde, 
D.M.; Renner, U.; Stalla, J.; Stalla, G.K.; Savino, W. Hypothala-
mus-pituitary-adrenal axis during trypanosoma cruzi acute infec-
tion in mice. J. Neuroimmunol., 2006, 173(1-2), 12-22. 
[134] Correa-de-Santana, E.; Paez-Pereda, M.; Theodoropoulou, M.; 
Renner, U.; Stalla, J.; Stalla, G.K.; Savino, W. Modulation of 
growth hormone and prolactin secretion in T. cruzi-infected mam-
mosomatotrophic cells. Neuroimmunomodulation, 2009, 16(3), 
208-212. 
[135] Frare, E.O.; Santello, F.H.; Caetano, L.C.; Caldeira, J.C.; Toldo, 
M.P.; Prado, J.C.Jr. Growth hormones therapy in immune response 
against Trypanosoma cruzi. Res. Vet. Sci., 2010, 88(2), 273-278. 
[136] Lemos ,E.M.; Reis, D.; Adad, S.J.; Silva, G.C.; Crema, E.; Correa-
Oliveira, R. Decreased CD4+ circulating T lymphocytes in patients 
with gastrointestinal chagas disease. Clin. Immunol. Immunopa-
thol., 1998, 88(2), 150-155. 
[137] Mendes-da-Cruz, D.A.; Silva, J.S.; Cotta-de-Almeida, V.; Savino, 
W. Altered thymocyte migration during experimental acute try-
panosoma cruzi infection: Combined role of fibronectin and the 
chemokines CXCL12 and CCL4. Eur. J. Immunol., 2006, 36,1486-
1493. 
[138] Mendes-da-Cruz, D.A.; de Meis, J.; Cotta-de-Almeida, V.; Savino, 
W. Experimental trypanosoma cruzi infection alters the shaping of 
the central and peripheral t-cell repertoire. Microbes Infect., 2003, 
5, 825-832 
[139] Fernandez-Mestre, M.T.; Jaraquemada, D.; Bruno, R.E.; Caro, J.; 
Layrisse, Z. Analysis of the t-cell receptor beta-chain variable-
region (Vbeta) repertoire in chronic human chagas' disease. Tissue 
Antigens, 2002, 60, 10-15.  
[140] Costa, R.P.; Gollob, K.J.; Fonseca, L.L.; Rocha, M.O.; Chaves, 
A.C.; Medrano-Mercado, N.; Araujo-Jorge, T.C.; Antas, P.R., Col-
ley, D.G.; Correa-Oliveira, R.; Gazzinelli, G., Carvalho-Parra, J.; 
Dutra, W.O. T-cell repertoire analysis in acute and chronic human 
chagas' disease: Differential frequencies of Vbeta5 expressing T 
cells. Scand. J. Immunol., 2000, 51, 511-519. 
 
 
Received: August 09, 2010    Revised: October 21, 2010                Accepted: October 30, 2010 
 
 
